Technology
DeepNeo
DeepNeoVx® is Neogenlogic’s platform for personalized cancer vaccines. At its core lies the DeepNeo system — a suite of AI solutions including DeepNeo-MHC, DeepNeo-TCR, and DeepNeo-BCR. Going beyond simple MHC binding prediction, DeepNeo identifies neoantigens capable of activating both T cells and B cells. Through this systematic approach, DeepNeoVx® is evolving as the world’s most advanced platform for providing optimal vaccines for each patient’s cancer.
DeepNeo System
- Neogenlogic’s proprietary AI system, DeepNeo, discovers tumor-specific neoantigens with verified immunogenicity and designs mRNA or peptide-based therapeutic vaccines targeting these antigens.
- The DeepNeo system consists of the DeepNeo-MHC/TCR module, which predicts MHC binding affinity and T-cell reactivity, and the DeepNeo-BCR module, which predicts B-cell reactivity.
- Aiming to identify true neoantigens, the DeepNeo system offers cost-efficient and highly accurate neoantigen prediction compared to existing algorithms, showing particularly improved performance in predicting MHC class II binding and B-cell reactivity.
DeepNeo-MHC/TCR
- DeepNeo-MHC/TCR consists of two modules: DeepNeo-MHC, which predicts physical binding to MHC, and DeepNeo-TCR, which predicts T-cell immune responses.
- Based on protein structural information, it predicts both MHC binding strength and immunogenicity.
DeepNeo-BCR
- DeepNeo-BCR collects large-scale human B-cell receptor (BCR) sequences, extracts the most significant clones, and models them by incorporating somatic hypermutation data.
- Peptide and B-cell receptor binding, along with the resulting immune response, is predicted using protein structural information.
